<DOC>
	<DOCNO>NCT01825928</DOCNO>
	<brief_summary>Methamphetamine substance use common worldwide . No approved pharmacologic treatment methamphetamine dependence exist . paliperidone Second generation antipsychotics，and effect block dopamine2 ( D2 ) 5-hydroxytryptamine 2A ( 5-HT ) receptor neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among methamphetamine addict .</brief_summary>
	<brief_title>An Study Paliperidone Extended-Release Tablets Treatment Methamphetamine Dependence</brief_title>
	<detailed_description>Methods : A Multiple-Center , Randomized , Double-Blind .</detailed_description>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Men woman age 18 year 60 year Met Diagnostic Statistical Manual Mental Disorders 4th edition ( DSMIV ) criteria METH dependence psychosis Completing inpatient METH detoxification ( ≤30 day ) psychotic symptom disappear Beoff antipsychotic medication 7 day discharge hospital enrol clinical site Participants interest reduce stop METH use Every patient also significant ( eg. , spouse relative ) supervise compliance visit schedule study procedure Women childbearing potential agree use contraception study . Exclusion criterion : Pregnancy breastfeeding ; Significant medical condition ( eg. , acute renal failure , endocarditis , tuberculosis ) ; hepatic failure ; past present history AIDSindicator disease ; active hepatitis aspartate amino transferase alanine aminotransferase three time upper limit normal Known intolerance hypersensitivity paliperidone ER ; psychosis ; present dependence substance METH polysubstance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Methamphetamine</keyword>
	<keyword>paliperidone</keyword>
</DOC>